hyperuricaemia


Also found in: Dictionary, Encyclopedia, Wikipedia.
Related to hyperuricaemia: uric acid, purine

hyperuricaemia, hyperuricemia

See gout.

hy·per·u·ri·ce·mi·a

(hī'pĕr-yūr'i-sē'mē-ă)
Enhanced blood concentrations of uric acid.
Synonym(s): hyperuricaemia.

hyperuricaemia

An abnormal level of uric acid in the blood, as a result of serum urate levels that exceed the limit of solubility. This results in the deposition of crystals of monosodium urate monohydrate in joints and tendons, causing GOUT. Hyperuricaemia is most commonly due to a genetically determined defect in the excretion of urates by the kidneys.

hyperuricaemia

increased blood levels of urate (i.e. >0.42 mmol/L); characteristic of chronic tophaceous gout, myeloma or cytotoxic medication; treated with allopurinol
References in periodicals archive ?
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Asymptomatic Hyperuricaemia can be with elevated uric acid in the absence of gout, elevated uric acid in the absence of chronic conditions and most patients with Hyperuricaemia have chronic conditions.
As shown in Tables 1 and 2, high dietary fructose induced metabolic syndrome in mice, characterized by dyslipidaemia, insulin resistance and hyperuricaemia.
Prevalence of hyperuricaemia and relation of serum uric acid in a developing country.
Hyperuricaemia and risk of cardiovascular disease and overall death.
Uric acid - hyperuricaemia is commonly associated with MetS and has been postulated to play a causal role.
The transaction, which saw Ardea going private, brings lesinurad, a potential next-generation treatment for the chronic hyperuricaemia in patients with gout, to AstraZeneca's late-stage pipeline, the buyer said.
The acquisition of San Diego, California-based Ardea is intended to strengthen AstraZeneca's late-stage pipeline with the addition of lesinurad, a potential next-generation treatment for the chronic management of hyperuricaemia in patients with gout.
Ardea's clinically most advanced product candidate, lesinurad (formerly known as RDEA594), is currently in phase 3 development as a potential treatment for the chronic management of hyperuricaemia in patients with gout.
Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia.
The seriousness and the high mortality rate of AHS warrants carefully evaluation before administration of allopurinol in cases of asymptomatic hyperuricaemia, particularly in patients with chronic renal failure (1,2).
Commonly affected systems are kidney (manifested by reduced GFR, proteinuria, hyperuricaemia and occasionally oliguria), liver (manifested by elevated transaminases with or without epigastric and right upper quadrant pain), and the brain (manifested by headaches, transient visual disturbances due to occipital lobe ischaemia and rarely convulsions, i.